Mesenchymal Stem Cell

"Koma zuwa Pipeline

OQORY™ (COVI-MSC) (Acute Respiratory Distress Syndrome)

Sorrento yana shiga gwaji na Mataki na I na OQORY™ (COVI-MSC) ga majinyata masu fama da Mutuwar Ciwon Hankali (ARDS) mai alaƙa da COVID-19, waɗanda FDA ta share.

Babban makasudin binciken na Mataki na 1 shine kimanta amincin jiko na jiko na allogeneic adipose stem cell a cikin marasa lafiya tare da COVID-19 kuma cikin damuwa na numfashi. Manufar na biyu ita ce kimanta saitin aminci da ingantaccen sakamako masu canji don ba da jagora game da haɗarin / fa'ida a cikin marasa lafiya da ke fama da matsalar numfashi ta COVID-19.

An nuna ƙwayoyin ƙwayoyin cuta don tallafawa ƙuduri na alamun bayyanar cututtuka a cikin saitunan cututtuka masu yawa kuma suna da damar rage tasirin da ke tattare da lalacewa na huhu na huhu ga waɗannan marasa lafiya. MSC tana wakiltar tsarin jiyya tare da babban yuwuwar taimakawa a cikin yaƙi da COVID-19 azaman jiyya na kaɗaita ko cikin haɗin gwiwa tare da wasu 'yan takarar samfur a cikin bututun Sorrento, gami da ƙananan ƙwayoyin cuta (abivertinib ko salicyn-30) da kawar da ƙwayoyin rigakafi (STI- 1499 ko STI 2020).